Johnson & Johnson’s investigational prostate cancer drug JNJ-6143 shows promising signs of tumour shrinkage in an early-stage trial, according to reports from both outlets. The early trial results describe substantial PSA reductions among evaluable participants receiving a 50-milligram dose, including many patients achieving large declines.
NDTV reports that, among 31 evaluable patients, 77% saw a PSA decline of at least 50%, and 48% recorded reductions of 90% or more. Investing.com also characterises the findings as promising, focusing on tumour responses and signalling potential effectiveness at this early point, though it does not add additional numerical detail in the summary provided.
Together, the coverage frames JNJ-6143 as an investigational therapy with encouraging early biomarker and response signals, while keeping emphasis on that it is still early trial evidence rather than confirmatory results from later-stage studies.
